These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9126699)

  • 1. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004].
    Yamaguchi K; Murakami M; Takahashi A; Ishii Y; Iwata M; Itoh K; Oohara T; Watanabe N; Uehara N; Nomura F; Watanabe M; Yasujima M; Kasai T; Kanno H; Aihara M; Suwabe A; Yamahata K; Maesaki S; Hashikita G; Kaku M; Kanemitsu K; Miyake K; Oguri T; Yoshida H; Nishiyama K; Okada J; Tazawa Y; Komatsu M; Nakashima H; Takemura H; Kinoshita S; Okada M; Kobayashi S; Taminato T; Negayama K; Horii T; Murase M; Miyamoto H; Baba H; Kusano N; Mihara E; Ishigo S; Kambe M; Itaha H; Fujita N; Komori T; Ono J; Yoshimura H; Ichiyama S; Maeda S; Hirakata Y; Matsuda J; Yamanaka K; Mutara Y; Saikawa T; Hiramatsu K; Taminato S
    Jpn J Antibiot; 2005 Dec; 58(6):655-89. PubMed ID: 16521347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
    Rhomberg PR; Jones RN;
    Diagn Microbiol Infect Dis; 2003 Sep; 47(1):365-72. PubMed ID: 12967752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
    Bauernfeind A; Jungwirth R; Schweighart S
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
    Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
    Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].
    Yamaguchi K; Ishii Y; Iwata M; Watanabe N; Shinagawa M; Yasujima M; Suwabe A; Kuroda M; Kaku M; Kitagawa M; Kanemitsu K; Imafuku Y; Murakami M; Yomodu S; Taniguchi N; Yamada T; Nomura F; Kanno H; Maesaki S; Hashikita G; Kondo S; Misawa S; Horiuchi H; Tazawa Y; Nakashima H; Takemura H; Okada M; Horikawa Y; Maekawa M; Nagura O; Yagi T; Baba H; Ishigo S; Fujita N; Komori T; Ichiyama S; Yamanaka K; Murata Y; Matsuo S; Kohno H; Kawano S; Kinoshita S; Taminato T; Negayama K; Murase M; Miyamoto H; Kusano N; Nose M; Yokozaki M; Itaha H; Matsunaga A; Yoshimura H; Kohno S; Yanagihara K; Matsuda J; Saikawa T; Hiramatsu K
    Jpn J Antibiot; 2011 Apr; 64(2):53-95. PubMed ID: 21721247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial in vitro-activity of meropenem against 200 clinical isolates in comparison to 11 selected antibiotics.
    Lang C; Beuth J; Ko HL; Tunggal L; Pulverer G
    Zentralbl Bakteriol; 1992 Dec; 277(4):485-92. PubMed ID: 1303691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom.
    King A; Boothman C; Phillips I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():31-45. PubMed ID: 2808214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the in vitro spectrum of activity of imipenem.
    Jones RN
    Am J Med; 1985 Jun; 78(6A):22-32. PubMed ID: 3890537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.